Your browser doesn't support javascript.
loading
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Bahcall, Magda; Paweletz, Cloud P; Kuang, Yanan; Taus, Luke J; Sim, Taebo; Kim, Nam Doo; Dholakia, Kshiti H; Lau, Christie J; Gokhale, Prafulla C; Chopade, Pratik R; Hong, Fangxin; Wei, Zihan; Köhler, Jens; Kirschmeier, Paul T; Guo, Jiannan; Guo, Sujuan; Wang, Stephen; Jänne, Pasi A.
Afiliación
  • Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Paweletz CP; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kuang Y; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Taus LJ; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Sim T; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim ND; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Dholakia KH; VORONOI BIO Inc., Incheon, Republic of Korea.
  • Lau CJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gokhale PC; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Chopade PR; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hong F; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wei Z; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Köhler J; Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Kirschmeier PT; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Guo J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Guo S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wang S; Resolution Bioscience, Kirkland, Washington.
  • Jänne PA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mol Cancer Ther ; 21(2): 322-335, 2022 02.
Article en En | MEDLINE | ID: mdl-34789563
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Secuenciación de Nucleótidos de Alto Rendimiento / Simulación del Acoplamiento Molecular Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Inhibidores de Proteínas Quinasas / Secuenciación de Nucleótidos de Alto Rendimiento / Simulación del Acoplamiento Molecular Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos